The exact dosing schedule should be individualized by the treating physician based on the patients needs
Research indicates that BPC-157 increases actin production at the gene level, while TB-500 acts as an actin-binding protein that facilitates cellular movement
Peptides can be customized for different outcomes
While the peptide does not increase IGF-1, caution is warranted given the theoretical relationship between growth factors and cancer progression
Common Contraindications Active or recent cancer (BPC-157 and TB-500 angiogenesis concern), Wilson's disease or other copper metabolism disorders (GHK-Cu component), pregnancy or breastfeeding (no safety data for any component), and competitive sport at WADA-tested levels (BPC-157 and TB-500 are listed under WADA category S0 Unapproved Substances) are commonly cited reasons not to research KLOW
Prescription drugs should only be used under the care of a licensed health care professional because they are intended to treat specific conditions and may cause serious side effects